The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins

LS Harrington, GM Findlay, A Gray… - The Journal of cell …, 2004 - rupress.org
LS Harrington, GM Findlay, A Gray, T Tolkacheva, S Wigfield, H Rebholz, J Barnett…
The Journal of cell biology, 2004rupress.org
Insulin-like growth factors elicit many responses through activation of phosphoinositide 3-
OH kinase (PI3K). The tuberous sclerosis complex (TSC1-2) suppresses cell growth by
negatively regulating a protein kinase, p70S6K (S6K1), which generally requires PI3K
signals for its activation. Here, we show that TSC1-2 is required for insulin signaling to PI3K.
TSC1-2 maintains insulin signaling to PI3K by restraining the activity of S6K, which when
activated inactivates insulin receptor substrate (IRS) function, via repression of IRS-1 gene …
Insulin-like growth factors elicit many responses through activation of phosphoinositide 3-OH kinase (PI3K). The tuberous sclerosis complex (TSC1-2) suppresses cell growth by negatively regulating a protein kinase, p70S6K (S6K1), which generally requires PI3K signals for its activation. Here, we show that TSC1-2 is required for insulin signaling to PI3K. TSC1-2 maintains insulin signaling to PI3K by restraining the activity of S6K, which when activated inactivates insulin receptor substrate (IRS) function, via repression of IRS-1 gene expression and via direct phosphorylation of IRS-1. Our results argue that the low malignant potential of tumors arising from TSC1-2 dysfunction may be explained by the failure of TSC mutant cells to activate PI3K and its downstream effectors.
rupress.org